Global Intraoperative Radiation Therapy Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|全球手術中放射線治療(IORT)市場:2021年∼2028年 Global Intraoperative Radiation Therapy Market - 2021-2028|
|出版日期: 2021年06月01日||內容資訊: 英文 180 Pages||
The global intraoperative radiation therapy market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Intraoperative radiation therapy (IORT) is an intensive radiation therapy that is administered through surgery. IORT allows direct radiation to the target area while sparing normal surrounding tissue. IORT is used to treat cancers that are difficult to separate during surgery and when there is a concern that microscopic amounts of cancer may remain.
The major factors driving the growth of this market are the increase in the predominance rate of cancer across the globe and demand for highly efficient radiation therapy systems for cancer treatment and new product approvals as radiation therapy is used in nearly 50% of all cancer treatments.
The rising incidence of cancer across the globe will drive the market growth
The increasing number of cancer cases such as breast cancer, prostate cancer, and lung cancer globally is expected to fuel the market's growth over the forecast period. As per the World Health Organization, in 2018, approximately 9.6 million deaths recorded over the globe were due to cancer. Furthermore, the National Cancer Institute prognosticated that in 2018, around 1,735,350 new cancer cases would be diagnosed in the US. Additionally, lung cancer is expected to increase the number of new cancer rate cases by 439.2 per 100,000 cases per year.
About 1.9 million new cancer cases and 693,000 cancer deaths were reported in 2018 in North America. Prostate cancers are the most generally diagnosed cancers amongst males in North America. However, breast cancer remains leading cancer in females. As per the American Cancer Society estimates, breast cancer is the most prevalent type of cancer in the US as it caused morbidity in 234,087 people and led to 41,904 deaths in 2018.
Cancer usually develops in older people. 87% of all cancers in the United States are diagnosed in people 50 years or older. Certain behaviors also increase risk, such as eating an unhealthy diet or not being physically active. In the US, approximately 40 out of 100 men and 38 out of 100 women will develop cancer during their lifetime.
Growing applications of IORT in the treatment of cancer is driving the market growth
An increase in the need for highly effective radiation therapy systems for cancer therapy and new product endorsements are projected to increase the intraoperative radiation therapy market during the forecast period. IORT has found essential applications as breast-conserving surgery. Technological advancements in this field, linked with the growing applications of IORT, have appeared in the increasing collaboration among many manufacturers and research institutes to administer clinical trials to study the applicability and efficacy of IORT for different cancer types. The primary aim of these clinical trials is to investigate and evaluate the usefulness of IORT treatment over various cancer applications.
For instance, in 2019, IntraOp Medical, Inc. collaborated with the Massachusetts General Hospital, initiated a study to investigate the effectivity of electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer.
Shortage of well-trained and skilled oncologists will hamper the market
A high level of precision is needed to achieve maximum tumor control and assure minimal risk to normal tissue at each step of the process. Procedural errors can occur due to interconnectivity problems between different therapy planning and delivery and monitoring systems, increasing patient risks. These complexities incorporated with IORT pose a difficulty towards its widespread appropriation in cancer treatment is seen frequent due to the shortage of well-trained and skilled oncologists.
COVID-19 Impact Analysis
The COVID-19 pandemic has impacted the healthcare systems globally and also has a notable impact on the market. As per the article written in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that while the COVID-19 pandemic, there was a 46% reduction in the surgery of the six most prevalent cancer types including lung cancer. Additionally, the Centers for Disease Control and several medical professional organizations suggested that cancer screening and other health prevention services be postponed except the risks outweighed the benefits and ensure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Electron IORT segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Electron intraoperative radiation treatment utilizes electron radiation straight to the residual tumor or tumor bed while cancer surgery. Electron beams are suitable for intraoperative radiation therapy, as the dose falls off rapidly after the target site depending on the electron energy, therefore, forgiving underlying healthy tissue. One of the advantages of IORT is given at the time of operation when microscopic residual tumor cells are most vulnerable to destruction. IORT is also often used in combination with external beam radiotherapy (EBRT), resulting in less necessary doses and shorter treatment times.
Moreover, Cancer Research UK suggests that the population experiencing cancer is expected to increase in the future. As per the report, if current trends in the incidence of vital cancers and population growth are harmonious, it is predicted that there will be 27.5 million new cancer cases worldwide each year by 2040. Thus, this is an expansion of 61.7% from 2018 (17 million). Hence, with the growing prevalence of cancer globally, the requirement for novel therapies, like IORT, and their advantages over conventional methods, are supposed to increase if the awareness concerning these techniques increases.
Lung Cancer segment are expected to dominate the intraoperative radiation therapy market, by application, during the forecast period
Lung cancer still caused more deaths in 2017 than breast, prostate, brain colorectal cancers joined. The mortality drops were also dramatic for melanoma of the skin in the viewing of US Food and Drug Administration approval of novel therapies for metastatic disorder, escalating to 7% annually during 2013 into 2017 from 1% during 2006 by 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in people aged 65 years and older are especially striking because rates in this age group were rising before 2013. Thus growing casses of lung cancer will drive the market growth in the forecast priod.
North America region holds the largest market share in the global Intraoperative Radiation Therapy Market
North America region is dominating the global intraoperative radiation therapy market accounted for the largest market share in 2020, owing to the growing incidence of lung cancer in the region, the presence of key market players, and the launch of new commodities influence market growth in the region.
According to the American Cancer Society's estimation, the new lung cancer cases in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved, and the incidence of localized lung cancer has increased.
As per the American Lung Association (2018), approximately 541,000 Americans living today have been diagnosed with lung cancer at some point in their lives. The majority of lung cancer patients have been diagnosed within the last five years. Each year, tens of thousands of people are cured of non-small cell lung cancer (NSCLC) in the United States. Lung cancer is primarily a disease of the elderly. It indicates the burden of lung cancer in this country, resulting in the market's growth as there is a high demand for cancer treatment in the United States. Furthermore, associations such as the American Society for Radiation Oncology (ASTRO) have advocated the use of low-energy IORT, which has contributed to its increased adoption in North America.
The intraoperative radiation therapy market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Carl Zeiss AG, Ariane Medical Systems Ltd, Eckert & Ziegler, Elekta AB, GMV, Elekta AB (pub), iCAD Inc., Moffitt Cancer Center, Xoft, Xinjiang Ke LAN Shuang Yi Medical Technology Stock Co., Ltd, E-tech Industry CO., Ltd, Derma Optic and Electronic Technique Co., Ltd, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Intraoperative Radiation Therapy Market globally.
Intraoperative Radiation Therapy Market Key Companies to Watch
Ariane Medical Systems.
Overview: Ariane Medical Systems was incorporated in 2005. Since then, we have worked alongside our clinical partners to optimize the delivery of low-energy X-rays to accessible tumors. The Papillon 50 X-ray brachytherapy system was developed for the treatment of lower rectal cancers. The Papillon 50 is now treating patients in Denmark, France, Sweden, Switzerland and the UK.
Product Portfolio: The Company offers low cost, mobile, treatment delivery system, rectal treatment, intraoperative treatment, skin cancer treatments and other.
The global intraoperative radiation therapy market report would provide an access to an approx. 58 market data table, 61 figures and 200 pages.
LIST NOT EXHAUSTIVE